REFERENCES

1.. Cushing HW: The pituitary body and its disorders.  Philadelphia, JB Lippincott, 1912.

2.. Cushing HW: The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bulletin of the Johns Hopkins Hospital  1932; 1:137-195.

3.. Walters W, Wilder RM, Kepler EJ: The suprarenal cortical syndrome with presentation of ten cases. Ann Surg  1934; 100:670-688.

4.. Liddle GW, Nicholson WE, Island DP, et al: Clinical and laboratory studies of ectopic humoral syndromes. Recent Prog Horm Res  1969; 25:283-314.

5.. Howlett TA, Rees LH, Besser GM: Cushing's syndrome. Clin Endocrinol Metab  1985; 14:911-945.

6.. Bertagna X: New causes of Cushing's syndrome. N Engl J Med  1992; 327:1024-1025.

7.. Reznik Y, Allali-Zerah V, Chayvialle JA, et al: Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med  1992; 327:981-986.

8.. Lacroix A, Bolte E, Tremblay J, et al: Gastric inhibitory polypeptide-dependent cortisol hypersecretion—a new cause of Cushing's syndrome. N Engl J Med  1992; 327:974-980.

9.. Malchoff CD, Orth DN, Abboud C, et al: Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. Am J Med  1988; 84:760-764.

10.. Biller BM, Alexander JM, Zervas NT, et al: Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing's disease. J Clin Endocrinol Metab  1992; 75:1303-1309.

11.. Mampalam TJ, Tyrrell JB, Wilson CB: Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med  1988; 109:487-493.

12.. Young Jr WF, Scheithauer BW, Gharib H, et al: Cushing's syndrome due to primary multinodular corticotrope hyperplasia. Mayo Clin Proc  1988; 63:256-262.

13.. Asa SL, Ezzat S: The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev  1998; 19:798-827.

14.. Dahia PL, Grossman AB: The molecular pathogenesis of corticotroph tumors. Endocr Rev  1999; 20:136-155.

15.. Rabbitt EH, Ayuk J, Boelaert K, et al: Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. Oncogene  2003; 22:1663-1667.

16.. Korbonits M, Chahal HS, Kaltsas G, et al: Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab  2002; 87:2635-2643.

17.. Trautmann K, Thakker RV, Ellison DW, et al: Chromosomal aberrations in sporadic pituitary tumors. Int J Cancer  2001; 91:809-814.

18.. Metzger AK, Mohapatra G, Minn YA, et al: Multiple genetic aberrations including evidence of chromosome 11q13 rearrangement detected in pituitary adenomas by comparative genomic hybridization. J Neurosurg  1999; 90:306-314.

19.. Fan X, Paetau A, Aalto Y, et al: Gain of chromosome 3 and loss of 13q are frequent alterations in pituitary adenomas. Cancer Genet Cytogenet  2001; 128:97-103.

20.. Evans CO, Young AN, Brown MR, et al: Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab  2001; 86:3097-3107.

21.. Imura H: Ectopic hormone syndromes. Clin Endocrinol Metab  1980; 9:235-260.

22.. de Bustros A, Baylin SB: Hormone production by tumours: biological and clinical aspects. Clin Endocrinol Metab  1985; 14:221-256.

23.. Pearse AG: Common cytochemical and ultrastructural characteristics of cells producing polypeptide hormones (the APUD series) and their relevance to thyroid and ultimobranchial C cells and calcitonin. Proc R Soc Lond B Biol Sci  1968; 170:71-80.

24.. Pullan PT, Clement-Jones V, Corder R, et al: ACTH LPH and related peptides in the ectopic ACTH syndrome. Clin Endocrinol (Oxf)  1980; 13:437-445.

25.. Rees LH, Bloomfield GA, Gilkes JJ, et al: ACTH as a tumor marker. Ann N Y Acad Sci  1977; 297:603-620.

26.. Stewart MF, Crosby SR, Gibson S, et al: Small cell lung cancer cell lines secrete predominantly ACTH precursor peptides not ACTH. Br J Cancer  1989; 60:20-24.

27.. White A, Clark AJ, Stewart MF: The synthesis of ACTH and related peptides by tumours. Baillieres Clin Endocrinol Metab  1990; 4:1-27.

28.. DeBold CR, Menefee JK, Nicholson WE, et al: Proopiomelanocortin gene is expressed in many normal human tissues and in tumors not associated with ectopic adrenocorticotropin syndrome. Mol Endocrinol  1988; 2:862-870.

29.. de Keyzer Y, Bertagna X, Luton JP, et al: Variable modes of proopiomelanocortin gene transcription in human tumors. Mol Endocrinol  1989; 3:215-223.

30.. Clark AJ, Lavender PM, Besser GM, et al: Pro-opiomelanocortin mRNA size heterogeneity in ACTH-dependent Cushing's syndrome. J Mol Endocrinol  1989; 2:3-9.

31.. Clark AJ, Stewart MF, Lavender PM, et al: Defective glucocorticoid regulation of proopiomelanocortin gene expression and peptide secretion in a small cell lung cancer cell line. J Clin Endocrinol Metab  1990; 70:485-490.

32.. Roth KA, Newell DC, Dorin RI, et al: Aberrant production and regulation of proopiomelanocortin-derived peptides in ectopic Cushing's syndrome. Horm Metab Res  1988; 20:225-229.

33.. Melmed S, Yamashita S, Kovacs K, et al: Cushing's syndrome due to ectopic proopiomelanocortin gene expression by islet cell carcinoma of the pancreas. Cancer  1987; 59:772-778.

34.. Limper AH, Carpenter PC, Scheithauer B, et al: The Cushing syndrome induced by bronchial carcinoid tumors. Ann Intern Med  1992; 117:209-214.

35.. Asa SL, Kovacs K, Vale W, et al: Immunohistologic localization of corticotrophin-releasing hormone in human tumors. Am J Clin Pathol  1987; 87:327-333.

36.. Jessop DS, Cunnah D, Millar JG, et al: A phaeochromocytoma presenting with Cushing's syndrome associated with increased concentrations of circulating corticotrophin-releasing factor. J Endocrinol  1987; 113:133-138.

37.. Zangeneh F, Young Jr WF, Lloyd RV, et al: Cushing's syndrome due to ectopic production of corticotropin-releasing hormone in an infant with ganglioneuroblastoma. Endocr Pract  2003; 9:394-399.

38.. Wajchenberg BL, Mendonca BB, Liberman B, et al: Ectopic adrenocorticotropic hormone syndrome. Endocr Rev  1994; 15:752-787.

39.. Sidhu S, Gicquel C, Bambach CP, et al: Clinical and molecular aspects of adrenocortical tumourigenesis. ANZ J Surg  2003; 73:727-738.

40.. Beuschlein F, Reincke M, Karl M, et al: Clonal composition of human adrenocortical neoplasms. Cancer Res  1994; 54:4927-4932.

41.. Weiss LM, Medeiros LJ, Vickery Jr AL: Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol  1989; 13:202-206.

42.. Travis WD, Tsokos M, Doppman JL, et al: Primary pigmented nodular adrenocortical disease. A light and electron microscopic study of eight cases. Am J Surg Pathol  1989; 13:921-930.

43.. Stratakis CA, Boikos SA: Genetics of adrenal tumors associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias. Nat Clin Pract Endocrinol Metab  2007; 3:748-757.

44.. Kirk JM, Brain CE, Carson DJ, et al: Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J Pediatr  1999; 134:789-792.

45.. Weinstein LS, Shenker A, Gejman PV, et al: Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med  1991; 325:1688-1695.

46.. Boston BA, Mandel S, LaFranchi S, et al: Activating mutation in the stimulatory guanine nucleotide-binding protein in an infant with Cushing's syndrome and nodular adrenal hyperplasia. J Clin Endocrinol Metab  1994; 79:890-893.

47.. Swords FM, Baig A, Malchoff DM, et al: Impaired desensitization of a mutant adrenocorticotropin receptor associated with apparent constitutive activity. Mol Endocrinol  2002; 16:2746-2753.

48.. Findlay JC, Sheeler LR, Engeland WC, et al: Familial adrenocorticotropin-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab  1993; 76:189-191.

49.. Christopoulos S, Bourdeau I, Lacroix A: Aberrant expression of hormone receptors in adrenal Cushing's syndrome. Pituitary  2004; 7:225-235.

50.. Maschler I, Rosenmann E, Ehrenfeld EN: Ectopic functioning adrenocortico-myelolipoma in longstanding Nelson's syndrome. Clin Endocrinol (Oxf)  1979; 10:493-497.

51.. Lalau JD, Vieau D, Tenenbaum F, et al: A case of pseudo-Nelson's syndrome: cure of ACTH hypersecretion by removal of a bronchial carcinoid tumor responsible for Cushing's syndrome. J Endocrinol Invest  1990; 13:531-537.

52.. Adeyemi SD, Grange AO, Giwa-Osagie OF, et al: Adrenal rest tumour of the ovary associated with isosexual precocious pseudopuberty and cushingoid features. Eur J Pediatr  1986; 145:236-238.

53.. Contreras P, Altieri E, Liberman C, et al: Adrenal rest tumor of the liver causing Cushing's syndrome: treatment with ketoconazole preceding an apparent surgical cure. J Clin Endocrinol Metab  1985; 60:21-28.

54.. Marieb NJ, Spangler S, Kashgarian M, et al: Cushing's syndrome secondary to ectopic cortisol production by an ovarian carcinoma. J Clin Endocrinol Metab  1983; 57:737-740.

55.. Newell-Price J, Trainer P, Besser M, et al: The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev  1998; 19:647-672.

56.. Chrousos GP, Schuermeyer TH, Doppman J, et al: NIH conference. Clinical applications of corticotropin-releasing factor. Ann Intern Med  1985; 102:344-358.

57.. Gold PW, Gwirtsman H, Avgerinos PC, et al: Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. N Engl J Med  1986; 314:1335-1342.

58.. Gold PW, Loriaux DL, Roy A, et al: Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med  1986; 314:1329-1335.

59.. Luger A, Deuster PA, Kyle SB, et al: Acute hypothalamic-pituitary-adrenal responses to the stress of treadmill exercise. Physiologic adaptations to physical training. N Engl J Med  1987; 316:1309-1315.

60.. Invitti C, Giraldi FP, de Martin M, et al: Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab  1999; 84:440-448.

61.. Lindholm J, Juul S, Jorgensen JO, et al: Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab  2001; 86:117-123.

62.. Abeloff MD, Trump DL, Baylin SB: Ectopic adrenocorticotrophic (ACTH) syndrome and small cell carcinoma of the lung-assessment of clinical implications in patients on combination chemotherapy. Cancer  1981; 48:1082-1087.

63.. Dimopoulos MA, Fernandez JF, Samaan NA, et al: Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer  1992; 69:66-71.

64.. Janssen-Heijnen ML, Coebergh JW: The changing epidemiology of lung cancer in Europe. Lung Cancer  2003; 41:245-258.

65.. Ambrosi B, Faglia G: Epidemiology of pituitary tumours.   In: Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A, ed. Pituitary adenomas: New trends in basic and clinical research,  Amsterdam: Excerpta Medica; 1991.

66.. Etxabe J, Vazquez JA: Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf)  1994; 40:479-484.

67.. Plotz CM, Knowlton AI, Ragan C: The natural history of Cushing's syndrome. Am J Med  1952; 13:597-614.

68.. Leinung MC, Young Jr WF, Whitaker MD, et al: Diagnosis of corticotropin-producing bronchial carcinoid tumors causing Cushing's syndrome. Mayo Clin Proc  1990; 65:1314-1321.

69.. Ross EJ, Linch DC: Cushing's syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet  1982; 2:646-649.

70.. Urbanic RC, George JM: Cushing's disease—18 years’ experience. Medicine (Baltimore)  1981; 60:14-24.

71.. Soffer LJ, Iannaccone A, Gabrilove JL: Cushing's syndrome *1: A study of fifty patients. The American Journal of Medicine  1961; 30:129-146.

72.. Sprague RG, Randall RV, Salassa RM: Cushing's syndrome: review of 100 cases. Arch Intern Med  1956; 98:389-398.

73.. Nugent CA, Warner HR, Dunn JT, et al: PROBABILITY THEORY IN THE DIAGNOSIS OF CUSHING'S SYNDROME. J Clin Endocrinol Metab  1964; 24:621-627.

74.. Pecori GF, Pivonello R, Ambrogio AG, et al: The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf)  2007; 66:251-257.

75.. Rockall AG, Sohaib SA, Evans D, et al: Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome. Eur J Endocrinol  2003; 149:561-567.

76.. Roy-Camille R, Mazel C, Husson JL, et al: Symptomatic spinal epidural lipomatosis induced by a long-term steroid treatment. Review of the literature and report of two additional cases. Spine  1991; 16:1365-1371.

77.. Noel P, Pepersack T, Vanbinst A, et al: Spinal epidural lipomatosis in Cushing's syndrome secondary to an adrenal tumor. Neurology  1992; 42:1250-1251.

78.. Healy ME, Hesselink JR, Ostrup RC, et al: Demonstration by magnetic resonance of symptomatic spinal epidural lipomatosis. Neurosurgery  1987; 21:414-415.

79.. Pleasure DE, Walsh GO, Engel WK: Atrophy of skeletal muscle in patients with Cushing's syndrome. Arch Neurol  1970; 22:118-125.

80.. Muller R, Kugelberg E: Myopathy in Cushing's syndrome. J Neurol Neurosurg Psychiatry  1959; 22:314-319.

81.. Afifi AK, Bergman RA, Harvey JC: Steroid myopathy. Clinical, histologic and cytologic observations. Johns Hopkins Med J  1968; 123:158-173.

82.. Vertebral compression fractures with accelerated bone turnover in a patient with Cushing's disease. Am J Med  1980; 68:932-940.

83.. Kingsley GH, Hickling P: Polyarthropathy associated with Cushing's disease. Br Med J (Clin Res Ed)  1986; 292:1363.

84.. Phillips KA, Nance Jr EP, Rodriguez RM, et al: Avascular necrosis of bone: a manifestation of Cushing's disease. South Med J  1986; 79:825-829.

85.. Bertagna C, Orth DN: Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med  1981; 71:855-875.

86.. Starkman MN, Schteingart DE: Neuropsychiatric manifestations of patients with Cushing's syndrome. Relationship to cortisol and adrenocorticotropic hormone levels. Arch Intern Med  1981; 141:215-219.

87.. Starkman MN, Schteingart DE, Schork MA: Correlation of bedside cognitive and neuropsychological tests in patients with Cushing's syndrome. Psychosomatics  1986; 27:508-511.

88.. Haskett RF: Diagnostic categorization of psychiatric disturbance in Cushing's syndrome. Am J Psychiatry  1985; 142:911-916.

89.. Hudson JI, Hudson MS, Griffing GT, et al: Phenomenology and family history of affective disorder in Cushing's disease. Am J Psychiatry  1987; 144:951-953.

90.. Rubinow DR, Post RM, Savard R, et al: Cortisol hypersecretion and cognitive impairment in depression. Arch Gen Psychiatry  1984; 41:279-283.

91.. Kathol RG: Etiologic implications of corticosteroid changes in affective disorder. Psychiatr Med  1985; 3:135-162.

92.. Fallo F, Sonino N, Barzon L, et al: Effect of surgical treatment on hypertension in Cushing's syndrome. Am J Hypertens  1996; 9:77-80.

93.. Bakker RC, Gallas PR, Romijn JA, et al: Cushing's syndrome complicated by multiple opportunistic infections. J Endocrinol Invest  1998; 21:329-333.

94.. Graham BS, Tucker Jr WS: Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med  1984; 101:334-338.

95.. Sarlis NJ, Chanock SJ, Nieman LK: Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab  2000; 85:42-47.

96.. Kaltsas GA, Korbonits M, Isidori AM, et al: How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?. Clin Endocrinol (Oxf)  2000; 53:493-500.

97.. Halbreich U, Zumoff B, Kream J, et al: The mean 1300–1600 h plasma cortisol concentration as a diagnostic test for hypercortisolism. J Clin Endocrinol Metab  1982; 54:1262-1264.

98.. Liu JH, Kazer RR, Rasmussen DD: Characterization of the twenty-four hour secretion patterns of adrenocorticotropin and cortisol in normal women and patients with Cushing's disease. J Clin Endocrinol Metab  1987; 64:1027-1035.

99.. Refetoff S, Van Cauter E, Fang VS, et al: The effect of dexamethasone on the 24-hour profiles of adrenocorticotropin and cortisol in Cushing's syndrome. J Clin Endocrinol Metab  1985; 60:527-535.

100.. Mengden T, Hubmann P, Muller J, et al: Urinary free cortisol versus 17-hydroxycorticosteroids: a comparative study of their diagnostic value in Cushing's syndrome. Clin Investig  1992; 70:545-548.

101.. Evans PJ, Peters JR, Dyas J, et al: Salivary cortisol levels in true and apparent hypercortisolism. Clin Endocrinol (Oxf)  1984; 20:709-715.

102.. Christy NP, Laragh JH: Pathogenesis of hypokalemic alkalosis in Cushing's syndrome. Nord Hyg Tidskr  1961; 265:1083-1088.

103.. Stewart PM, Krozowski ZS: 11 beta-Hydroxysteroid dehydrogenase. Vitam Horm  1999; 57:249-324.

104.. Putignano P, Kaltsas GA, Korbonits M, et al: Alterations in serum protein levels in patients with Cushing's syndrome before and after successful treatment. J Clin Endocrinol Metab  2000; 85:3309-3312.

105.. Ambrosi B, Sartorio A, Pizzocaro A, et al: Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma. Exp Clin Endocrinol Diabetes  2000; 108:294-298.

106.. Casonato A, Pontara E, Boscaro M, et al: Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. Blood Coagul Fibrinolysis  1999; 10:145-151.

107.. Patrassi GM, Dal Bo ZR, Boscaro M, et al: Further studies on the hypercoagulable state of patients with Cushing's syndrome. Thromb Haemost  1985; 54:518-520.

108.. Taskinen MR, Nikkila EA, Pelkonen R, et al: Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing's syndrome. J Clin Endocrinol Metab  1983; 57:619-626.

109.. Friedman TC, Mastorakos G, Newman TD, et al: Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. Endocr J  1996; 43:645-655.

110.. Biering H, Knappe G, Gerl H, et al: [Prevalence of diabetes in acromegaly and Cushing syndrome]. Acta Med Austriaca  2000; 27:27-31.

111.. Krassowski J, Godziejewska M, Kurta J, et al: [Glucose tolerance in adrenocortical hyperfunction. Analysis of 100 cases]. Pol Arch Med Wewn  1994; 92:70-75.

112.. Catargi B, Rigalleau V, Poussin A, et al: Occult Cushing's syndrome in type-2 diabetes. J Clin Endocrinol Metab  2003; 88:5808-5813.

113.. Newsome S, Chen K, Hoang J, et al: Cushing's syndrome in a clinic population with diabetes. Intern Med J  2008; 38:178-182.

114.. Faggiano A, Pivonello R, Spiezia S, et al: Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab  2003; 88:2527-2533.

115.. Colao A, Pivonello R, Spiezia S, et al: Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab  1999; 84:2664-2672.

116.. Bartalena L, Martino E, Petrini L, et al: The nocturnal serum thyrotropin surge is abolished in patients with adrenocorticotropin (ACTH)-dependent or ACTH-independent Cushing's syndrome. J Clin Endocrinol Metab  1991; 72:1195-1199.

117.. Colao A, Pivonello R, Faggiano A, et al: Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clin Endocrinol (Oxf)  2000; 53:13-19.

118.. Niepomniszcze H, Pitoia F, Katz SB, et al: Primary thyroid disorders in endogenous Cushing's syndrome. Eur J Endocrinol  2002; 147:305-311.

119.. Luton JP, Thieblot P, Valcke JC, et al: Reversible gonadotropin deficiency in male Cushing's disease. J Clin Endocrinol Metab  1977; 45:488-495.

120.. Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, et al: Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab  1998; 83:3083-3088.

121.. Giustina A, Bossoni S, Bussi AR, et al: Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in patients with Cushing's disease. Endocr Res  1993; 19:47-56.

122.. Kaltsas G, Manetti L, Grossman AB: Osteoporosis in Cushing's syndrome. Front Horm Res  2002; 30:60-72.

123.. Ohmori N, Nomura K, Ohmori K, et al: Osteoporosis is more prevalent in adrenal than in pituitary Cushing's syndrome. Endocr J  2003; 50:1-7.

124.. Rockall AG, Sohaib SA, Evans D, et al: Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur J Endocrinol  2003; 149:543-548.

125.. Giraldi FP, Moro M, Cavagnini F: Gender-related differences in the presentation and course of Cushing's disease. J Clin Endocrinol Metab  2003; 88:1554-1558.

126.. King AB: The diagnosis of carcinoma of the pituitary gland. Bull Johns Hopkins Hosp  1951; 89:339-353.

127.. Martins AN, Hayes GJ, Kempe LG: INVASIVE PITUITARY ADENOMAS. J Neurosurg  1965; 22:268-276.

128.. Della CS, Corsello SM, Satta MA, et al: Intracranial and spinal dissemination of an ACTH secreting pituitary neoplasia. Case report and review of the literature. Ann Endocrinol (Paris)  1997; 58:503-509.

129.. Arnaldi G, Angeli A, Atkinson AB, et al: Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab  2003; 88:5593-5602.

130.. Besser GM, Edwards CRW: Cushing's Syndrome. Clin Endocrinol Metab  1972; 1:451-490.

131.. Lamberts SW, Klijn JG, de Jong FH, et al: Hormone secretion in alcohol-induced pseudo-Cushing's syndrome. Differential diagnosis with Cushing disease. JAMA  1979; 242:1640-1643.

132.. Wallace EZ, Rosman P, Toshav N, et al: Pituitary-adrenocortical function in chronic renal failure: studies of episodic secretion of cortisol and dexamethasone suppressibility. J Clin Endocrinol Metab  1980; 50:46-51.

133.. Werner S, Thoren M, Gustafsson JA, et al: Glucocorticoid receptor abnormalities in fibroblasts from patients with idiopathic resistance to dexamethasone diagnosed when evaluated for adrenocortical disorders. J Clin Endocrinol Metab  1992; 75:1005-1009.

134.. Nieman LK, Biller BM, Findling JW, et al: The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab  2008; 93:1526-1540.

135.. Murphy BE: Clinical evaluation of urinary cortisol determinations by competitive protein-binding radioassay. J Clin Endocrinol Metab  1968; 28:343-348.

136.. Orth DN: Cushing's syndrome. N Engl J Med  1995; 332:791-803.

137.. Contreras LN, Hane S, Tyrrell JB: Urinary cortisol in the assessment of pituitary-adrenal function: utility of 24-hour and spot determinations. J Clin Endocrinol Metab  1986; 62:965-969.

138.. Laudat MH, Billaud L, Thomopoulos P, et al: Evening urinary free corticoids: a screening test in Cushing's syndrome and incidentally discovered adrenal tumours. Acta Endocrinol (Copenh)  1988; 119:459-464.

139.. Lin CL, Wu TJ, Machacek DA, et al: Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab  1997; 82:151-155.

140.. Turpeinen U, Markkanen H, Valimaki M, et al: Determination of urinary free cortisol by HPLC. Clin Chem  1997; 43:1386-1391.

141.. Meikle AW, Findling J, Kushnir MM, et al: Pseudo-Cushing Syndrome Caused by Fenofibrate Interference with Urinary Cortisol Assayed by High-Performance Liquid Chromatography. J Clin Endocrinol Metab  2003; 88:3521-3524.

142..  Nieman LK, Cutler GB Jr: The sensitivity of the urine free cortisol measurement as a screening test for Cushing's syndrome, Program of the 72nd Annual Meeting of The Endocrine Society, Atlanta GA (Abstract P-822) 1990.

143.. Laudat MH, Cerdas S, Fournier C, et al: Salivary cortisol measurement: a practical approach to assess pituitary-adrenal function. J Clin Endocrinol Metab  1988; 66:343-348.

144.. Putignano P, Dubini A, Toja P, et al: Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol. Eur J Endocrinol  2001; 145:165-171.

145.. Raff H, Homar PJ, Skoner DP: New enzyme immunoassay for salivary cortisol. Clin Chem  2003; 49:203-204.

146.. Papanicolaou DA, Mullen N, Kyrou I, et al: Nighttime salivary cortisol: a useful test for the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab  2002; 87:4515-4521.

147.. Putignano P, Toja P, Dubini A, et al: Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing's syndrome. J Clin Endocrinol Metab  2003; 88:4153-4157.

148.. Raff H, Raff JL, Findling JW: Late-night salivary cortisol as a screening test for Cushing's syndrome. J Clin Endocrinol Metab  1998; 83:2681-2686.

149.. Castro M, Elias PC, Quidute AR, et al: Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab  1999; 84:878-882.

150.. Viardot A, Huber P, Puder JJ, et al: Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test. J Clin Endocrinol Metab  2005; 90:5730-5736.

151.. Trilck M, Flitsch J, Ludecke DK, et al: Salivary cortisol measurement–a reliable method for the diagnosis of Cushing's syndrome. Exp Clin Endocrinol Diabetes  2005; 113:225-230.

152.. Yaneva M, Mosnier-Pudar H, Dugue MA, et al: Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J Clin Endocrinol Metab  2004; 89:3345-3351.

153.. Baid SK, Sinaii N, Wade M, et al: Radioimmunoassay and tandem mass spectrometry measurement of bedtime salivary cortisol levels: a comparison of assays to establish hypercortisolism. J Clin Endocrinol Metab  2007; 92:3102-3107.

154.. Liu H, Bravata DM, Cabaccan J, et al: Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin Endocrinol (Oxf)  2005; 63:642-649.

155.. Liddle GW: Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab  1960; 20:1539-1560.

156.. Kennedy L, Atkinson AB, Johnston H, et al: Serum cortisol concentrations during low dose dexamethasone suppression test to screen for Cushing's syndrome. Br Med J (Clin Res Ed)  1984; 289:1188-1191.

157.. Hankin ME, Theile HM, Steinbeck AW: An evaluation of laboratory tests for the detection and differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf)  1977; 6:185-196.

158.. Newell-Price J, Trainer P, Perry L, et al: A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf)  1995; 43:545-550.

159.. Isidori AM, Kaltsas GA, Mohammed S, et al: Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab  2003; 88:5299-5306.

160.. Nugent CA, Nichols T, Tyler FH: Diagnosis of Cushing's syndrome—single dose dexamethasone suppression test. Arch Intern Med  1965.172-176.

161.. Shimizu N, Yoshida H: Studies on the “low dose” suppressible Cushing's disease. Endocrinol Jpn  1976; 23:479-484.

162.. McHardy-Young S, Harris PW, Lessof MH, et al: Single dose dexamethasone suppression test for Cushing's Syndrome. Br Med J  1967; 2:740-744.

163.. Seidensticker JF, Folk RL, Wieland RG, et al: Screening test for Cushing's syndrome with plasma 11-hydroxycorticosteroids. JAMA  1967; 202:87-90.

164.. Crapo L: Cushing's syndrome: a review of diagnostic tests. Metabolism  1979; 28:955-977.

165.. Odagiri E, Demura R, Demura H, et al: The changes in plasma cortisol and urinary free cortisol by an overnight dexamethasone suppression test in patients with Cushing's disease. Endocrinol Jpn  1988; 35:795-802.

166.. Martinelli Jr CE, Sader SL, Oliveira EB, et al: Salivary cortisol for screening of Cushing's syndrome in children. Clin Endocrinol (Oxf)  1999; 51:67-71.

167.. Putignano P, Kaltsas GA, Satta MA, et al: The effects of anti-convulsant drugs on adrenal function. Horm Metab Res  1998; 30:389-397.

168.. Abou Samra AB, Dechaud H, Estour B, et al: Beta-lipotropin and cortisol responses to an intravenous infusion dexamethasone suppression test in Cushing's syndrome and obesity. J Clin Endocrinol Metab  1985; 61:116-119.

169.. Atkinson AB, McAteer EJ, Hadden DR, et al: A weight-related intravenous dexamethasone suppression test distinguishes obese controls from patients with Cushing's syndrome. Acta Endocrinol (Copenh)  1989; 120:753-759.

170.. Klose M, Lange M, Rasmussen AK, et al: Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocrinol Metab  2007; 92:1326-1333.

171.. Yanovski JA, Cutler Jr GB, Chrousos GP, et al: Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA  1993; 269:2232-2238.

172..  Yanovski JA, Cutler GB Jr, Chrousos GP, et al: Prospective evaluation of the dexamethasone-suppressed corticotrophin-releasing hormone test in the differential diagnosis of Cushing's syndrome and pseudo-Cushing's states, Program of the 77th Annual Meeting of the Endocrine Society, Washington DC p 99 (abstract):1995.

173.. Martin NM, Dhillo WS, Banerjee A, et al: Comparison of the dexamethasone-suppressed corticotropin-releasing hormone test and low-dose dexamethasone suppression test in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab  2006; 91:2582-2586.

174..  Gatta B, Cortet C, Martinie M, et al: Reevaluation of the dex-CRH test for the differential diagnosis between Cushing's disease and pseudo-Cushing's syndrome. Program of the 88th Annual Meeting of The Endocrine Society, Boston, MA, 2006, P2–734 2006.

175.. Erickson D, Natt N, Nippoldt T, et al: Dexamethasone-suppressed corticotropin-releasing hormone stimulation test for diagnosis of mild hypercortisolism. J Clin Endocrinol Metab  2007; 92:2972-2976.

176.. Nieman L: Editorial: The dexamethasone-suppressed corticotropin-releasing hormone test for the diagnosis of Cushing's syndrome: what have we learned in 14 years?. J Clin Endocrinol Metab  2007; 92:2876-2878.

177.. Papanicolaou DA, Yanovski JA, Cutler Jr GB, et al: A single midnight serum cortisol measurement distinguishes Cushing's syndrome from pseudo-Cushing states. J Clin Endocrinol Metab  1998; 83:1163-1167.

178.. Reimondo G, Allasino B, Bovio S, et al: Evaluation of the effectiveness of midnight serum cortisol in the diagnostic procedures for Cushing's syndrome. Eur J Endocrinol  2005; 153:803-809.

179.. Ambrosi B, Bochicchio D, Ferrario R, et al: Effects of the opiate agonist loperamide on pituitary-adrenal function in patients with suspected hypercortisolism. J Endocrinol Invest  1989; 12:31-35.

180.. Ambrosi B, Bochicchio D, Colombo P, et al: Loperamide to diagnose Cushing's syndrome. JAMA  1993; 270:2301-2302.

181.. Bernini GP, Argenio GF, Cerri F, et al: Comparison between the suppressive effects of dexamethasone and loperamide on cortisol and ACTH secretion in some pathological conditions. J Endocrinol Invest  1994; 17:799-804.

182.. Lytras N, Grossman A, Perry L, et al: Corticotrophin releasing factor: responses in normal subjects and patients with disorders of the hypothalamus and pituitary. Clin Endocrinol (Oxf)  1984; 20:71-84.

183.. Fig LM, Gross MD, Shapiro B, et al: Adrenal localization in the adrenocorticotropic hormone-independent Cushing syndrome. Ann Intern Med  1988; 109:547-553.

184.. Perry RR, Nieman LK, Cutler Jr GB, et al: Primary adrenal causes of Cushing's syndrome. Diagnosis and surgical management. Ann Surg  1989; 210:59-68.

185.. Doppman JL, Miller DL, Dwyer AJ, et al: Macronodular adrenal hyperplasia in Cushing disease. Radiology  1988; 166:347-352.

186.. Mimou N, Sakato S, Nakabayashi H, et al: Cushing's syndrome associated with bilateral adrenal adenomas. Acta Endocrinol (Copenh)  1985; 108:245-254.

187.. Doppman JL, Travis WD, Nieman L, et al: Cushing syndrome due to primary pigmented nodular adrenocortical disease: findings at CT and MR imaging. Radiology  1989; 172:415-420.

188.. Doppman JL, Nieman LK, Travis WD, et al: CT and MR imaging of massive macronodular adrenocortical disease: a rare cause of autonomous primary adrenal hypercortisolism. J Comput Assist Tomogr  1991; 15:773-779.

189.. Sohaib SA, Hanson JA, Newell-Price JD, et al: CT appearance of the adrenal glands in adrenocorticotrophic hormone-dependent Cushing's syndrome. AJR Am J Roentgenol  1999; 172:997-1002.

190.. Aron DC, Findling JW, Fitzgerald PA, et al: Pituitary ACTH dependency of nodular adrenal hyperplasia in Cushing's syndrome. Report of two cases and review of the literature. Am J Med  1981; 71:302-306.

191.. Howlett TA, Drury PL, Perry L, et al: Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol (Oxf)  1986; 24:699-713.

192.. Newell-Price J, Morris DG, Drake WM, et al: Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab  2002; 87:1640-1645.

193.. Yamamoto Y, Davis DH, Nippoldt TB, et al: False-positive inferior petrosal sinus sampling in the diagnosis of Cushing's disease. Report of two cases. J Neurosurg  1995; 83:1087-1091.

194.. Yanovski JA, Cutler Jr GB, Doppman JL, et al: The limited ability of inferior petrosal sinus sampling with corticotropin-releasing hormone to distinguish Cushing's disease from pseudo-Cushing states or normal physiology. J Clin Endocrinol Metab  1993; 77:503-509.

195.. Miller DL, Doppman JL: Petrosal sinus sampling: technique and rationale. Radiology  1991; 178:37-47.

196.. Oldfield EH, Doppman JL, Nieman LK, et al: Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med  1991; 325:897-905.

197.. Kaltsas GA, Giannulis MG, Newell-Price JD, et al: A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab  1999; 84:487-492.

198.. Colao A, Faggiano A, Pivonello R, et al: Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: results of an Italian multicenter study. Eur J Endocrinol  2001; 144:499-507.

199.. Swearingen B, Katznelson L, Miller K, et al: Diagnostic errors after inferior petrosal sinus sampling. J Clin Endocrinol Metab  2004; 89:3752-3763.

200.. McCance DR, McIlrath E, McNeill A, et al: Bilateral inferior petrosal sinus sampling as a routine procedure in ACTH-dependent Cushing's syndrome. Clin Endocrinol (Oxf)  1989; 30:157-166.

201.. Findling JW, Kehoe ME, Raff H: Identification of patients with Cushing's disease with negative pituitary adrenocorticotropin gradients during inferior petrosal sinus sampling: prolactin as an index of pituitary venous effluent. J Clin Endocrinol Metab  2004; 89:6005-6009.

202.. Miller DL: Neurologic complications of petrosal sinus sampling. Radiology  1992; 183:878.

203.. Lefournier V, Gatta B, Martinie M, et al: One transient neurological complication (sixth nerve palsy) in 166 consecutive inferior petrosal sinus samplings for the etiological diagnosis of Cushing's syndrome. J Clin Endocrinol Metab  1999; 84:3401-3402.

204.. Rotman-Pikielny P, Patronas N, Papanicolaou DA: Pituitary apoplexy induced by corticotrophin-releasing hormone in a patient with Cushing's disease. Clin Endocrinol (Oxf)  2003; 58:545-549.

205.. Tabarin A, Greselle JF, San Galli F, et al: Usefulness of the corticotropin-releasing hormone test during bilateral inferior petrosal sinus sampling for the diagnosis of Cushing's disease. J Clin Endocrinol Metab  1991; 73:53-59.

206.. Landolt AM, Schubiger O, Maurer R, et al: The value of inferior petrosal sinus sampling in diagnosis and treatment of Cushing's disease. Clin Endocrinol (Oxf)  1994; 40:485-492.

207.. Lefournier V, Martinie M, Vasdev A, et al: Accuracy of bilateral inferior petrosal or cavernous sinuses sampling in predicting the lateralization of Cushing's disease pituitary microadenoma: influence of catheter position and anatomy of venous drainage. J Clin Endocrinol Metab  2003; 88:196-203.

208.. Morris DG, Grossman AB: Dynamic tests in the diagnosis and differential diagnosis of Cushing's syndrome. J Endocrinol Invest  2003; 26:64-73.

209.. Miller DL, Doppman JL, Nieman LK, et al: Petrosal sinus sampling: discordant lateralization of ACTH-secreting pituitary microadenomas before and after stimulation with corticotropin-releasing hormone. Radiology  1990; 176:429-431.

210.. Erickson D, Huston III J, Young Jr WF, et al: Internal jugular vein sampling in adrenocorticotropic hormone-dependent Cushing's syndrome: a comparison with inferior petrosal sinus sampling. Clin Endocrinol (Oxf)  2004; 60:413-419.

211.. Ilias I, Chang R, Pacak K, et al: Jugular venous sampling: an alternative to petrosal sinus sampling for the diagnostic evaluation of adrenocorticotropic hormone-dependent Cushing's syndrome. J Clin Endocrinol Metab  2004; 89:3795-3800.

212.. Tyrrell JB, Findling JW, Aron DC, et al: An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome. Ann Intern Med  1986; 104:180-186.

213.. Aron DC, Raff H, Findling JW: Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab  1997; 82:1780-1785.

214.. Kaye TB, Crapo L: The Cushing syndrome: an update on diagnostic tests. Ann Intern Med  1990; 112:434-444.

215.. Giraldi FP, Invitti C, Cavagnini F: The corticotropin-releasing hormone test in the diagnosis of ACTH- dependent Cushing's syndrome: a reappraisal. Clin Endocrinol (Oxf)  2001; 54:601-607.

216.. Ilias I, Torpy DJ, Pacak K, et al: Cushing's syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institutes of Health. J Clin Endocrinol Metab  2005; 90:4955-4962.

217.. Trainer PJ, Faria M, Newell-Price J, et al: A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis. J Clin Endocrinol Metab  1995; 80:412-417.

218.. Trainer PJ, Woods RJ, Korbonits M, et al: The pathophysiology of circulating corticotropin-releasing hormone-binding protein levels in the human. J Clin Endocrinol Metab  1998; 83:1611-1614.

219.. Nieman LK, Oldfield EH, Wesley R, et al: A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab  1993; 77:1308-1312.

220.. Korbonits M, Kaltsas G, Perry LA, et al: The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab  1999; 84:2489-2495.

221.. Korbonits M, Bustin SA, Kojima M, et al: The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab  2001; 86:881-887.

222.. Tabarin A, San Galli F, Dezou S, et al: The corticotropin-releasing factor test in the differential diagnosis of Cushing's syndrome: a comparison with the lysine-vasopressin test. Acta Endocrinol (Copenh)  1990; 123:331-338.

223.. Malerbi DA, Mendonca BB, Liberman B, et al: The desmopressin stimulation test in the differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf)  1993; 38:463-472.

224.. Ghigo E, Arvat E, Ramunni J, et al: Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab  1997; 82:2439-2444.

225.. Castinetti F, Morange I, Dufour H, et al: Desmopressin test during petrosal sinus sampling: a valuable tool to discriminate pituitary or ectopic ACTH-dependent Cushing's syndrome. Eur J Endocrinol  2007; 157:271-277.

226.. Newell-Price J, Perry L, Medbak S, et al: A combined test using desmopressin and corticotropin-releasing hormone in the differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab  1997; 82:176-181.

227.. Tsagarakis S, Tsigos C, Vasiliou V, et al: The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion. J Clin Endocrinol Metab  2002; 87:1646-1653.

228.. Korbonits M, Jacobs RA, Aylwin SJB, et al: Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors. J Clin Endocrinol Metab  1998; 83:3624-3630.

229.. Nieman LK, Chrousos GP, Oldfield EH, et al: The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome. Ann Intern Med  1986; 105:862-867.

230.. Hermus AR, Pieters GF, Pesman GJ, et al: The corticotropin-releasing-hormone test versus the high-dose dexamethasone test in the differential diagnosis of Cushing's syndrome. Lancet  1986; 2:540-544.

231.. Grossman AB, Howlett TA, Perry L, et al: CRF in the differential diagnosis of Cushing's syndrome: a comparison with the dexamethasone suppression test. Clin Endocrinol (Oxf)  1988; 29:167-178.

232.. Doppman JL, Frank JA, Dwyer AJ, et al: Gadolinium DTPA enhanced MR imaging of ACTH-secreting microadenomas of the pituitary gland. J Comput Assist Tomogr  1988; 12:728-735.

233.. Patronas N, Bulakbasi N, Stratakis CA, et al: Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J Clin Endocrinol Metab  2003; 88:1565-1569.

234.. Hall WA, Luciano MG, Doppman JL, et al: Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med  1994; 120:817-820.

235.. Findling JW, Doppman JL: Biochemical and radiologic diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am  1994; 23:511-537.

236.. Escourolle H, Abecassis JP, Bertagna X, et al: Comparison of computerized tomography and magnetic resonance imaging for the examination of the pituitary gland in patients with Cushing's disease. Clin Endocrinol (Oxf)  1993; 39:307-313.

237.. Doppman JL, Pass HI, Nieman LK, et al: Detection of ACTH-producing bronchial carcinoid tumors: MR imaging vs CT. AJR Am J Roentgenol  1991; 156:39-43.

238.. Doppman JL, Nieman L, Miller DL, et al: Ectopic adrenocorticotropic hormone syndrome: localization studies in 28 patients. Radiology  1989; 172:115-124.

239.. de Herder WW, Lamberts SW: Octapeptide somatostatin-analogue therapy of Cushing's syndrome. Postgrad Med J  1999; 75:65-66.

240.. Tabarin A, Valli N, Chanson P, et al: Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab  1999; 84:1193-1202.

241.. Tsagarakis S, Christoforaki M, Giannopoulou H, et al: A reappraisal of the utility of somatostatin receptor scintigraphy in patients with ectopic adrenocorticotropin Cushing's syndrome. J Clin Endocrinol Metab  2003; 88:4754-4758.

242.. Torpy DJ, Chen CC, Mullen N, et al: Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. J Clin Endocrinol Metab  1999; 84:1186-1192.

243.. Kumar J, Spring M, Carroll PV, et al: 18Fluorodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clin Endocrinol (Oxf)  2006; 64:371-374.

244.. Pacak K, Ilias I, Chen CC, et al: The role of [(18)F]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome. J Clin Endocrinol Metab  2004; 89:2214-2221.

245.. Sarkar R, Thompson NW, McLeod MK: The role of adrenalectomy in Cushing's syndrome. Surgery  1990; 108:1079-1084.

246.. Terzolo M, Reimondo G, Bovio S, et al: Subclinical Cushing's syndrome. Pituitary  2004; 7:217-223.

247.. Biller BM, Grossman AB, Stewart PM, et al: Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement. J Clin Endocrinol Metab  2008; 93:2454-2462.

248.. Lamberts SW, van der Lely AJ, de Herder WW: Transsphenoidal selective adenomectomy is the treatment of choice in patients with Cushing's disease. Considerations concerning preoperative medical treatment and the long-term follow-up. J Clin Endocrinol Metab  1995; 80:3111-3113.

249.. Boscaro M, Sonino N, Scarda A, et al: Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab  2002; 87:3662-3666.

250.. Welbourn RB: The evolution of transsphenoidal pituitary microsurgery. Surgery  1986; 100:1185-1190.

251.. Fahlbusch R, Buchfelder M, Muller OA: Transsphenoidal surgery for Cushing's disease. J R Soc Med  1986; 79:262-269.

252.. Knappe UJ, Ludecke DK: Persistent and recurrent hypercortisolism after transsphenoidal surgery for Cushing's disease. Acta Neurochir Suppl  1996; 65:31-34.

253.. Stevenaert A, Perrin G, Martin D, et al: [Cushing's disease and corticotrophic adenoma: results of pituitary microsurgery]. Neurochirurgie  2002; 48:234-265.

254.. Swearingen B, Biller BM, Barker FG, et al: Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med  1999; 130:821-824.

255.. Hammer GD, Tyrrell JB, Lamborn KR, et al: Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab  2004; 89:6348-6357.

256.. Hofmann BM, Fahlbusch R: Treatment of Cushing's disease: a retrospective clinical study of the latest 100 cases. Front Horm Res  2006; 34:158-184.

257.. Bochicchio D, Losa M, Buchfelder M: Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab  1995; 80:3114-3120.

258.. Sonino N, Zielezny M, Fava GA, et al: Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab  1996; 81:2647-2652.

259.. Blevins Jr LS, Christy JH, Khajavi M, et al: Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas. J Clin Endocrinol Metab  1998; 83:63-67.

260.. Netea-Maier RT, van Lindert EJ, den Heijer M, et al: Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing's disease. Eur J Endocrinol  2006; 154:675-684.

261.. Oldfield EH, Vortmeyer AO: Development of a histological pseudocapsule and its use as a surgical capsule in the excision of pituitary tumors. J Neurosurg  2006; 104:7-19.

262.. Atkinson AB, Kennedy A, Wiggam MI, et al: Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf)  2005; 63:549-559.

263.. Rees DA, Hanna FW, Davies JS, et al: Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf)  2002; 56:541-551.

264.. Hughes NR, Lissett CA, Shalet SM: Growth hormone status following treatment for Cushing's syndrome. Clin Endocrinol (Oxf)  1999; 51:61-66.

265.. Pereira AM, van Aken MO, van Dulken H, et al: Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease. J Clin Endocrinol Metab  2003; 88:5858-5864.

266.. Esposito F, Dusick JR, Cohan P, et al: Clinical review: Early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab  2006; 91:7-13.

267.. Avgerinos PC, Chrousos GP, Nieman LK, et al: The corticotropin-releasing hormone test in the postoperative evaluation of patients with Cushing's syndrome. J Clin Endocrinol Metab  1987; 65:906-913.

268..  Nieman LK, Gumowski J, DeVroom H, et al: Prediction of long-term remission of Cushing's disease after successful transsphenoidal resection of ACTH-secreting tumor. Presented at the 80th Annual Meeting of the Endocrine Society P345: New Orleans, LA, 1998.

269.. Colombo P, Dall’Asta C, Barbetta L, et al: Usefulness of the desmopressin test in the postoperative evaluation of patients with Cushing's disease. Eur J Endocrinol  2000; 143:227-234.

270.. Losa M, Mortini P, Dylgjeri S, et al: Desmopressin stimulation test before and after pituitary surgery in patients with Cushing's disease. Clin Endocrinol (Oxf)  2001; 55:61-68.

271.. Byyny RL: Withdrawal from glucocorticoid therapy. N Engl J Med  1976; 295:30-32.

272.. Papanicolaou DA, Tsigos C, Oldfield EH, et al: Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency?. J Clin Endocrinol Metab  1996; 81:2303-2306.

273.. Leshin M: Acute adrenal insufficiency: recognition, management, and prevention. Urol Clin North Am  1982; 9:229-235.

274.. Lindsay JR, Nansel T, Baid S, et al: Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab  2006; 91:447-453.

275.. Olson BR, Rubino D, Gumowski J, et al: Isolated hyponatremia after transsphenoidal pituitary surgery. J Clin Endocrinol Metab  1995; 80:85-91.

276.. Manning PJ, Evans MC, Reid IR: Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol (Oxf)  1992; 36:229-234.

277.. Di Somma C, Pivonello R, Loche S, et al: Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol (Oxf)  2003; 58:302-308.

278.. Di Somma C, Colao A, Pivonello R, et al: Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Clin Endocrinol (Oxf)  1998; 48:655-662.

279.. Ram Z, Nieman LK, Cutler Jr GB, et al: Early repeat surgery for persistent Cushing's disease. J Neurosurg  1994; 80:37-45.

280.. Locatelli M, Vance ML, Laws ER: Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab  2005; 90:5478-5482.

281.. Doherty GM, Nieman LK, Cutler Jr GB, et al: Time to recovery of the hypothalamic-pituitary-adrenal axis after curative resection of adrenal tumors in patients with Cushing's syndrome. Surgery  1990; 108:1085-1090.

282.. Plumpton FS, Besser GM: The adrenocortical response to surgery and insulin-induced hypoglycemia in corticosteroid-treated and normal subjects. Br J Surg  1968; 55:857.

283.. Bangar V, Clayton RN: How reliable is the short synacthen test for the investigation of the hypothalamic-pituitary-adrenal axis?. Eur J Endocrinol  1998; 139:580-583.

284.. Kehlet H, Lindholm J, Bjerre P: Value of the 30 min ACTH-test in assessing hypothalamic-pituitary-adrenocortical function after pituitary surgery in Cushing's disease. Clin Endocrinol (Oxf)  1984; 20:349-353.

285.. Stewart PM, Corrie J, Seckl JR, et al: A rational approach for assessing the hypothalamo-pituitary-adrenal axis. Lancet  1988; 1:1208-1210.

286.. Orme SM, Peacey SR, Barth JH, et al: Comparison of tests of stress-released cortisol secretion in pituitary disease. Clin Endocrinol (Oxf)  1996; 45:135-140.

287.. Ammari F, Issa BG, Millward E, Scanion MF: A comparison between short ACTH and insulin stress tests for assessing hypothalamo-pituitary-adrenal function. Clin Endocrinol (Oxf)  1996; 44:473-476.

288.. Timmers HJ, van Ginneken EM, Wesseling P, et al: A patient with recurrent hypercortisolism after removal of an ACTH-secreting pituitary adenoma due to an adrenal macronodule. J Endocrinol Invest  2006; 29:934-939.

289.. Valimaki M, Pelkonen R, Porkka L, et al: Long-term results of adrenal surgery in patients with Cushing's syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf)  1984; 20:229-236.

290.. Bellantone R, Ferrante A, Boscherini M, et al: Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery  1997; 122:1212-1218.

291.. McCallum RW, Connell JM: Laparoscopic adrenalectomy. Clin Endocrinol (Oxf)  2001; 55:435-436.

292.. Wells SA, Merke DP, Cutler Jr GB, et al: Therapeutic controversy: The role of laparoscopic surgery in adrenal disease. J Clin Endocrinol Metab  1998; 83:3041-3049.

293.. Kemink L, Pieters G, Hermus A, et al: Patient's age is a simple predictive factor for the development of Nelson's syndrome after total adrenalectomy for Cushing's disease. J Clin Endocrinol Metab  1994; 79:887-889.

294.. Assie G, Bahurel H, Coste J, et al: Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome. J Clin Endocrinol Metab  2007; 92:172-179.

295.. Jenkins PJ, Trainer PJ, Plowman PN, et al: The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab  1995; 80:165-171.

296.. Sheline GE, Wara WM, Smith V: Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys  1980; 6:1215-1228.

297.. Orth DN, Liddle GW: Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med  1971; 285:243-247.

298.. Howlett TA, Plowman PN, Wass JA, et al: Megavoltage pituitary irradiation in the management of Cushing's disease and Nelson's syndrome: long-term follow-up. Clin Endocrinol (Oxf)  1989; 31:309-323.

299.. Murayama M, Yasuda K, Minamori Y, et al: Long term follow-up of Cushing's disease treated with reserpine and pituitary irradiation. J Clin Endocrinol Metab  1992; 75:935-942.

300.. Littley MD, Shalet SM, Beardwell CG, et al: Long-term follow-up of low-dose external pituitary irradiation for Cushing's disease. Clin Endocrinol (Oxf)  1990; 33:445-455.

301.. Estrada J, Boronat M, Mielgo M, et al: The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med  1997; 336:172-177.

302.. Mahmoud-Ahmed AS, Suh JH: Radiation therapy for Cushing's disease: a review. Pituitary  2002; 5:175-180.

303.. Plowman PN: Pituitary adenoma radiotherapy—when, who and how?. Clin Endocrinol (Oxf)  1999; 51:265-271.

304.. Becker G, Kocher M, Kortmann RD, et al: Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol  2002; 178:173-186.

305.. Marks LB: Conventional fractionated radiation therapy vs. radiosurgery for selected benign intracranial lesions (arteriovenous malformations, pituitary adenomas, and acoustic neuromas). J Neurooncol  1993; 17:223-230.

306.. Jagannathan J, Sheehan JP, Pouratian N, et al: Gamma Knife surgery for Cushing's disease. J Neurosurg  2007; 106:980-987.

307.. Petit JH, Biller BM, Yock TI, et al: Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab  2008; 93:393-399.

308.. Swords FM, Allan CA, Plowman PN, et al: Stereotactic Radiosurgery XVI: A Treatment for Previously Irradiated Pituitary Adenomas. J Clin Endocrinol Metab  2003; 88:5334-5340.

309.. Sandler LM, Richards NT, Carr DH, et al: Long term follow-up of patients with Cushing's disease treated by interstitial irradiation. J Clin Endocrinol Metab  1987; 65:441-447.

310.. Molinatti GM, Limone P, Porta M: Treatment of Cushing's disease by interstitial pituitary irradiation: short- and long-term follow-up. Panminerva Med  1995; 37:1-7.

311.. Magee BJ, Gattamaneni HR, Pearson D: Adrenal cortical carcinoma: survival after radiotherapy. Clin Radiol  1987; 38:587-588.

312.. de Castro F, Isa W, Aguera L, et al: [Primary adrenal carcinoma]. Actas Urol Esp  1993; 17:30-34.

313.. He J, Zhou J, Lu Z: Radiotherapy of ectopic ACTH syndrome due to thoracic carcinoids. Chin Med J (Engl)  1995; 108:338-341.

314.. Andres R, Mayordomo JI, Cajal S, et al: Paraneoplastic Cushing's syndrome associated to locally advanced thymic carcinoid tumor. Tumori  2002; 88:65-67.

315.. Misbin RI, Canary J, Willard D: Aminoglutethimide in the treatment of Cushing's syndrome. J Clin Pharmacol  1976; 16:645-651.

316.. Semple CG, Beastall GH, Gray CE, et al: Trilostane in the management of Cushing's syndrome. Acta Endocrinol (Copenh)  1983; 102:107-110.

317.. Carballeira A, Fishman LM, Jacobi JD: Dual sites of inhibition by metyrapone of human adrenal steroidogenesis: correlation of in vivo and in vitro studies. J Clin Endocrinol Metab  1976; 42:687-695.

318.. Verhelst JA, Trainer PJ, Howlett TA, et al: Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf)  1991; 35:169-178.

319.. Jeffcoate WJ, Rees LH, Tomlin S, et al: Metyrapone in long-term management of Cushing's disease. Br Med J  1977; 2:215-217.

320.. Feldman D: Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev  1986; 7:409-420.

321.. Engelhardt D, Weber MM, Miksch T, et al: The influence of ketoconazole on human adrenal steroidogenesis: incubation studies with tissue slices. Clin Endocrinol (Oxf)  1991; 35:163-168.

322.. Steen RE, Kapelrud H, Haug E, et al: In vivo and in vitro inhibition by ketoconazole of ACTH secretion from a human thymic carcinoid tumour. Acta Endocrinol (Copenh)  1991; 125:331-334.

323.. Sonino N, Boscaro M, Paoletta A, et al: Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf)  1991; 35:347-352.

324.. Tabarin A, Navarranne A, Guerin J, et al: Use of ketoconazole in the treatment of Cushing's disease and ectopic ACTH syndrome. Clin Endocrinol (Oxf)  1991; 34:63-69.

325.. Ahmed M, Kanaan I, Alarifi A, et al: ACTH-producing pituitary cancer: experience at the King Faisal Specialist Hospital & Research Centre. Pituitary  2000; 3:105-112.

326.. Lewis JH, Zimmerman HJ, Benson GD, et al: Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology  1984; 86:503-513.

327.. Duarte PA, Chow CC, Simmons F, et al: Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med  1984; 144:1069-1070.

328.. Knight TE, Shikuma CY, Knight J: Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol  1991; 25:398-400.

329.. McCance DR, Ritchie CM, Sheridan B, et al: Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. Lancet  1987; 1:573.

330.. Tucker Jr WS, Snell BB, Island DP, et al: Reversible adrenal insufficiency induced by ketoconazole. JAMA  1985; 253:2413-2414.

331.. Miettinen TA: Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res  1988; 29:43-51.

332.. Riedl M, Maier C, Zettinig G, et al: Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol  2006; 154:519-524.

333.. Hart MM, Swackhamer ES, Straw JA: Studies on the site of action of o,p′-DDD in the dog adrenal cortex. II. Steroids  1971; 17:575-586.

334.. Ojima M, Saitoh M, Itoh N, et al: [The effects of o,p′-DDD on adrenal steroidogenesis and hepatic steroid metabolism]. Nippon Naibunpi Gakkai Zasshi  1985; 61:168-178.

335.. Bergenstal DM, Hertz R, Lipsett MB, et al: Chemotherapy of adrenocortical cancer with O,p′DDD. Ann Intern Med  1960; 53:672-682.

336.. Gutierrez ML, Crooke ST: Mitotane (o,p′-DDD). Cancer Treat Rev  1980; 7:49-55.

337.. Kasperlik-Zaluska AA: Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res  2000; 33:1191-1196.

338.. Terzolo M, Angeli A, Fassnacht M, et al: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med  2007; 356:2372-2380.

339.. van Slooten H, Moolenaar AJ, van Seters AP, et al: The treatment of adrenocortical carcinoma with o,p′-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol  1984; 20:47-53.

340.. Bukowski RM, Wolfe M, Levine HS, et al: Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol  1993; 11:161-165.

341.. Berruti A, Terzolo M, Pia A, et al: Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer  1998; 83:2194-2200.

342.. Williamson SK, Lew D, Miller GJ, et al: Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer  2000; 88:1159-1165.

343.. Luton JP, Mahoudeau JA, Bouchard P, et al: Treatment of Cushing's disease by O,p′DDD. Survey of 62 cases. N Engl J Med  1979; 300:459-464.

344.. Schteingart DE, Tsao HS, Taylor CI, et al: Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med  1980; 92:613-619.

345.. Carey RM, Orth DN, Hartmann WH: Malignant melanoma with ectopic production of adrenocorticotropic hormone. Palliative treatment with inhibitors of adrenal steroid biosynthesis. J Clin Endocrinol Metab  1973; 36:482-487.

346.. Hutter Jr AM, Kayhoe DE: Adrenal cortical carcinoma. Results of treatment with o,p′DDD in 138 patients. Am J Med  1966; 41:581-592.

347.. Luton JP, Cerdas S, Billaud L, et al: Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med  1990; 322:1195-1201.

348.. Haak HR, Caekebeke-Peerlinck KM, van Seters AP, et al: Prolonged bleeding time due to mitotane therapy. Eur J Cancer  1991; 27:638-641.

349.. Maher VM, Trainer PJ, Scoppola A, et al: Possible mechanism and treatment of o,p′DDD-induced hypercholesterolaemia. Q J Med  1992; 84:671-679.

350.. Leiba S, Weinstein R, Shindel B, et al: The protracted effect of o,p′-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann Endocrinol (Paris)  1989; 50:49-53.

351.. van Seters AP, Moolenaar AJ: Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol (Copenh)  1991; 124:526-533.

352.. Hague RV, May W, Cullen DR: Hepatic microsomal enzyme induction and adrenal crisis due to o,p′DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol (Oxf)  1989; 31:51-57.

353.. Ledingham IM, Watt I: Influence of sedation on mortality in critically ill multiple trauma patients. Lancet  1983; 1:1270.

354.. Weber MM, Lang J, Abedinpour F, et al: Different inhibitory effect of etomidate and ketoconazole on the human adrenal steroid biosynthesis. Clin Investig  1993; 71:933-938.

355.. Lamberts SW, Bons EG, Bruining HA, et al: Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther  1987; 240:259-264.

356.. Schulte HM, Benker G, Reinwein D, et al: Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab  1990; 70:1426-1430.

357.. Allolio B, Schulte HM, Kaulen D, et al: Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome. Klin Wochenschr  1988; 66:361-364.

358.. Herrmann BL, Mitchell A, Saller B, et al: [Transsphenoidal hypophysectomy of a patient with an ACTH-producing pituitary adenoma and an “empty sella” after pretreatment with etomidate]. Dtsch Med Wochenschr  2001; 126:232-234.

359.. Drake WM, Perry LA, Hinds CJ, et al: Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. J Clin Endocrinol Metab  1998; 83:3542-3544.

360.. Krakoff J, Koch CA, Calis KA, et al: Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. J Clin Endocrinol Metab  2001; 86:4104-4108.

361.. Greening JE, Brain CE, Perry LA, et al: Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease. Horm Res  2005; 64:140-143.

362.. Sartor O, Cutler Jr GB: Mifepristone: treatment of Cushing's syndrome. Clin Obstet Gynecol  1996; 39:506-510.

363.. Waveren Hogervorst CO, Koppeschaar HP, Zelissen PM, et al: Cortisol secretory patterns in Cushing's disease and response to cyproheptadine treatment. J Clin Endocrinol Metab  1996; 81:652-655.

364.. Sonino N, Fava GA, Fallo F, et al: Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. Pituitary  2000; 3:55-59.

365.. Mercado-Asis LB, Yasuda K, Murayama M, et al: Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease. Endocrinol Jpn  1992; 39:385-395.

366.. Pivonello R, Ferone D, de Herder WW, et al: Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab  2004; 89:2452-2462.

367.. Colao A, Pivonello R, Tripodi FS, et al: Failure of long-term therapy with sodium valproate in Cushing's disease. J Endocrinol Invest  1997; 20:387-392.

368.. Greenman Y, Melmed S: Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab  1994; 78:398-403.

369.. Lamberts SW, de Herder WW, Krenning EP, et al: A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome. J Clin Endocrinol Metab  1994; 78:17-19.

370.. de Herder WW, Lamberts SW: Is there a role for somatostatin and its analogs in Cushing's syndrome?. Metabolism  1996; 45:83-85.

371.. Batista DL, Zhang X, Gejman R, et al: The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab  2006; 91:4482-4488.

372.. Boscaro M, Atkinson AB, Bertherat J, et al: SOM230 Cushing's disease study group. Early data on the efficacy and safety of the novel multi-ligand somatostatin analog SOM230 in patients with Cushing's disease.  87th Annual Meeting of The Endocrine Society, San Diego, CA, June 4–7, 2005, P2-6722005.

373.. Boscaro M, Glusman JE, Ludlam W, et al: Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): A multicenter, phase II trial. J Clin Endocrinol Metab  2009; 94:115-122.

374.. Heaney AP, Fernando M, Yong WH, et al: Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med  2002; 8:1281-1287.

375.. Suri D, Weiss RE: Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab  2005; 90:1340-1346.

376.. Ambrosi B, Dall’Asta C, Cannavo S, et al: Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol  2004; 151:173-178.

377.. Pecori GF, Scaroni C, Arvat E, et al: Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. Clin Endocrinol (Oxf)  2006; 64:219-224.

378.. Morcos M, Fohr B, Tafel J, et al: Long-term treatment of central Cushing's syndrome with rosiglitazone. Exp Clin Endocrinol Diabetes  2007; 115:292-297.

379.. Munir A, Song F, Ince P, et al: Ineffectiveness of rosiglitazone therapy in Nelson's syndrome. J Clin Endocrinol Metab  2007; 92:1758-1763.

380.. Sonino N, Boscaro M, Fallo F: Pharmacologic management of Cushing syndrome: new targets for therapy. Treat Endocrinol  2005; 4:87-94.

381.. Paez-Pereda M, Kovalovsky D, Hopfner U, et al: Retinoic acid prevents experimental Cushing syndrome. J Clin Invest  2001; 108:1123-1131.

382.. Castillo V, Giacomini D, Paez-Pereda M, et al: Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology  2006; 147:4438-4444.

383.. Shapiro MS, Shenkman L: Variable hormonogenesis in Cushing's syndrome. Q J Med  1991; 79:351-363.

384.. Kammer H, Barter M: Spontaneous remission of Cushing's disease. A case report and review of the literature. Am J Med  1979; 67:519-523.

385.. Hayslett JP, Cohn GL: Spontaneous remission of Cushing's disease. Report of a case. N Engl J Med  1967; 276:968-970.

386.. Meinardi JR, Wolffenbuttel BH, Dullaart RP: Cyclic Cushing's syndrome: a clinical challenge. Eur J Endocrinol  2007; 157:245-254.

387.. Brown RD, Van Loon GR, Orth DN, et al: Cushing's disease with periodic hormonogenesis: one explanation for paradoxical response to dexamethasone. J Clin Endocrinol Metab  1973; 36:445-451.

388.. Vagnucci AH, Evans E: Cushing's disease with intermittent hypercortisolism. Am J Med  1986; 80:83-88.

389.. Kreze A, Veleminsky J, Spirova E: A follow-up of the “low dose suppressible” hypercortisolism. Endocrinol Exp  1983; 17:119-123.

390.. Tsuruoka S, Sugimoto K, Fujimura A: Drug-induced Cushing syndrome in a patient with ulcerative colitis after betamethasone enema: evaluation of plasma drug concentration. Ther Drug Monit  1998; 20:387-389.

391.. Findlay CA, Macdonald JF, Wallace AM, et al: Childhood Cushing's syndrome induced by betamethasone nose drops, and repeat prescriptions. BMJ  1998; 317:739-740.

392.. Quddusi S, Browne P, Toivola B, et al: Cushing syndrome due to surreptitious glucocorticoid administration. Arch Intern Med  1998; 158:294-296.

393.. McConkey B: Adrenal corticosteroids in Chinese herbal remedies. QJM  2003; 96:81-82.

394.. Mann M, Koller E, Murgo A, et al: Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med  1997; 157:1651-1656.

395.. Cizza G, Nieman LK, Doppman JL, et al: Factitious Cushing syndrome. J Clin Endocrinol Metab  1996; 81:3573-3577.

396.. O’Hare JP, Vale JA, Wood S, et al: Factitious Cushing's syndrome. Acta Endocrinol (Copenh)  1986; 111:165-167.

397.. Sharp NA, Devlin JT, Rimmer JM: Renal failure obfuscates the diagnosis of Cushing's disease. JAMA  1986; 256:2564-2565.

398.. Otokida K, Fujiwara T, Oriso S, et al: Cortisol and its metabolites in the plasma and urine in Cushing's syndrome with chronic renal failure (CRF), compared to Cushing's syndrome without CRF. Nippon Jinzo Gakkai Shi  1989; 31:651-656.

399.. Jain S, Sakhuja V, Bhansali A, et al: Corticotropin-dependent Cushing's syndrome in a patient with chronic renal failure–a rare association. Ren Fail  1993; 15:563-566.

400.. Luger A, Lang I, Kovarik J, et al: Abnormalities in the hypothalamic-pituitary-adrenocortical axis in patients with chronic renal failure. Am J Kidney Dis  1987; 9:51-54.

401.. Siamopoulos KC, Dardamanis M, Kyriaki D, et al: Pituitary adrenal responsiveness to corticotropin-releasing hormone in chronic uremic patients. Perit Dial Int  1990; 10:153-156.

402.. Nolan GE, Smith JB, Chavre VJ, et al: Spurious overestimation of plasma cortisol in patients with chronic renal failure. J Clin Endocrinol Metab  1981; 52:1242-1245.

403.. Sederberg-Olsen P, Binder C, Kehlet H: Urinary excretion of free cortisol in impaired renal function. Acta Endocrinol (Copenh)  1975; 78:86-90.

404.. Ramirez G, Gomez-Sanchez C, Meikle WA, et al: Evaluation of the hypothalamic hypophyseal adrenal axis in patients receiving long-term hemodialysis. Arch Intern Med  1982; 142:1448-1452.

405.. Workman RJ, Vaughn WK, Stone WJ: Dexamethasone suppression testing in chronic renal failure: pharmacokinetics of dexamethasone and demonstration of a normal hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab  1986; 63:741-746.

406.. Rosman PM, Farag A, Peckham R, et al: Pituitary-adrenocortical function in chronic renal failure: blunted suppression and early escape of plasma cortisol levels after intravenous dexamethasone. J Clin Endocrinol Metab  1982; 54:528-533.

407.. Rodger RS, Dewar JH, Turner SJ, et al: Anterior pituitary dysfunction in patients with chronic renal failure treated by hemodialysis or continuous ambulatory peritoneal dialysis. Nephron  1986; 43:169-172.

408.. Streeten DH, Faas FH, Elders MJ, et al: Hypercortisolism in childhood: shortcomings of conventional diagnostic criteria. Pediatrics  1975; 56:797-803.

409.. Magiakou MA, Mastorakos G, Oldfield EH, et al: Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med  1994; 331:629-636.

410.. Weber A, Trainer PJ, Grossman AB, et al: Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome. Clin Endocrinol (Oxf)  1995; 43:19-28.

411.. Lee PD, Winter RJ, Green OC: Virilizing adrenocortical tumors in childhood: eight cases and a review of the literature. Pediatrics  1985; 76:437-444.

412.. Savage MO, Lienhardt A, Lebrethon MC, et al: Cushing's disease in childhood: presentation, investigation, treatment and long-term outcome. Horm Res  2001; 55(Suppl 1)):24-30.

413.. Storr HL, Chan LF, Grossman AB, et al: Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances. Trends Endocrinol Metab  2007; 18:167-174.

414.. Gafni RI, Papanicolaou DA, Nieman LK: Nighttime salivary cortisol measurement as a simple, noninvasive, outpatient screening test for Cushing's syndrome in children and adolescents. J Pediatr  2000; 137:30-35.

415.. Batista DL, Riar J, Keil M, et al: Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics  2007; 120:e575-e586.

416.. Carpenter PC: Diagnostic evaluation of Cushing's syndrome. Endocrinol Metab Clin North Am  1988; 17:445-472.

417.. Dias R, Storr HL, Perry LA, et al: The discriminatory value of the low-dose dexamethasone suppression test in the investigation of paediatric Cushing's syndrome. Horm Res  2006; 65:159-162.

418.. Hanson JA, Weber A, Reznek RH, et al: Magnetic resonance imaging of adrenocortical adenomas in childhood: correlation with computed tomography and ultrasound. Pediatr Radiol  1996; 26:794-799.

419.. Storr HL, Afshar F, Matson M, et al: Factors influencing cure by transsphenoidal selective adenomectomy in paediatric Cushing's disease. Eur J Endocrinol  2005; 152:825-833.

420.. Storr HL, Plowman PN, Carroll PV, et al: Clinical and endocrine responses to pituitary radiotherapy in pediatric Cushing's disease: an effective second-line treatment. J Clin Endocrinol Metab  2003; 88:34-37.

421.. Davies JH, Storr HL, Davies K, et al: Final adult height and body mass index after cure of paediatric Cushing's disease. Clin Endocrinol (Oxf)  2005; 62:466-472.

422.. Scommegna S, Greening JP, Storr HL, et al: Bone mineral density at diagnosis and following successful treatment of pediatric Cushing's disease. J Endocrinol Invest  2005; 28:231-235.

423.. Lindsay JR, Nieman LK: The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr Rev  2005; 26:775-799.

424.. Lindsay JR, Jonklaas J, Oldfield EH, et al: Cushing's syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab  2005; 90:3077-3083.

425.. Welbourn RB, Montgomery DA, Kennedy TL: The natural history of treated Cushing's syndrome. Br J Surg  1971; 58:1-16.

426.. Heald AH, Ghosh S, Bray S, et al: Long-term negative impact on quality of life in patients with successfully treated Cushing's disease. Clin Endocrinol (Oxf)  2004; 61:458-465.

427.. Wick MR, Rosai J: Neuroendocrine neoplasms of the thymus. Pathol Res Pract  1988; 183:188-199.

428.. Jex RK, van Heerden JA, Carpenter PC, et al: Ectopic ACTH syndrome, Diagnostic and therapeutic aspects. Am J Surg  1985; 149:276-282.

429.. Torpy DJ, Mullen N, Ilias I, et al: Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: a series of 58 cases. Ann N Y Acad Sci  2002; 970:134-144.

430.. Morris DG, Grossman AB: Cushing's syndrome—The diagnosis and differential diagnosis.   In: Gaillard RC, ed. The ACTH Axis: Pathogenesis, Diagnosis and Treatment,  Hingham: Kluwer; 2003:270.